January 2025 in “Clinical and Experimental Vaccine Research” A woman experienced total hair loss after an HPV vaccine, but treatment helped regrow her hair.
January 2025 in “Annals of Dermatology” Low-dose dutasteride effectively and safely promotes hair growth in men.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “Mansoura Medical Journal” Minoxidil is more effective than cetirizine for treating male hair loss.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
January 2025 in “Aesthetic Surgery Journal Open Forum” Liposuction and fat grafting safely improve back muscle definition and body contour.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
Topical GT20029 effectively promotes hair regrowth and is well-tolerated.
January 2025 in “Journal of Cosmetic Dermatology” The supplement improved hair growth and quality in men with thinning hair and was safe to use.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “Figshare” Compound glycyrrhizin combined with conventional treatments effectively and safely promotes hair regrowth in alopecia areata patients.
January 2025 in “Figshare” Compound glycyrrhizin with conventional treatments is effective and safe for promoting hair regrowth in alopecia areata.
December 2024 in “Biological and Clinical Sciences Research Journal” Injectable platelet-rich fibrin (I-PRF) is more effective than platelet-rich plasma (PRP) for treating hair loss.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Cryotherapy with precise temperature control is a promising treatment for alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
November 2024 in “Journal of Cosmetic Dermatology” Regenerative medicine is effective and safe for treating vitiligo.
Poly-L-lactic acid injections can cause hair loss and skin issues.
November 2024 in “PubMed” The supplement improved hair density and was safe to use.
October 2024 in “International Journal of Research in Dermatology” Mintop serum effectively reduces hair fall and promotes new growth safely.
October 2024 in “Dermatologic Surgery” Exosomes might help with hair loss, but more research is needed to confirm their safety and effectiveness.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
October 2024 in “Skin Appendage Disorders” PRP is popular for hair restoration but needs better research methods to confirm its effectiveness and safety.
October 2024 in “Journal of the Endocrine Society” A single steroid injection can cause serious side effects like Cushing Syndrome.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
September 2024 in “Journal of Cosmetic Dermatology” The new hair product quickly reduces hair shedding in women.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.